Corvus Pharmaceuticals Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Corvus Pharmaceuticals de winst en omzet met respectievelijk 12.1% en 78.7% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 20% per jaar.

Belangrijke informatie

12.1%

Groei van de winst

20.0%

Groei van de winst per aandeel

Biotechs winstgroei	28.4%
Inkomstengroei	78.7%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	13 Nov 2024

Recente toekomstige groei-updates

Recent updates

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Oct 23

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

May 16

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Dec 05

Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China

Sep 26

We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Aug 14

Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

Apr 05

We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Dec 15

Checking In On Corvus Pharmaceuticals

Dec 10

Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming

Sep 22

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Aug 26

Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target

May 27

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

May 08

The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Feb 19

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Feb 07

Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Dec 16

Corvus Pharmaceuticals EPS misses by $0.06

Oct 29

Winst- en omzetgroeiprognoses

NasdaqGM:CRVS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	3	-50	-9	N/A	4
12/31/2025	1	-35	3	N/A	4
12/31/2024	N/A	-58	-7	N/A	4
9/30/2024	N/A	-57	-22	-22	N/A
6/30/2024	N/A	-23	-21	-21	N/A
3/31/2024	N/A	-25	-21	-21	N/A
12/31/2023	N/A	-27	-24	-24	N/A
9/30/2023	N/A	-30	-26	-26	N/A
6/30/2023	N/A	-39	-28	-28	N/A
3/31/2023	N/A	-41	-29	-29	N/A
12/31/2022	N/A	-41	-27	-27	N/A
9/30/2022	N/A	-41	-27	-26	N/A
6/30/2022	N/A	-37	-28	-28	N/A
3/31/2022	N/A	-40	-34	-34	N/A
12/31/2021	N/A	-43	-37	-37	N/A
9/30/2021	N/A	-7	-38	-38	N/A
6/30/2021	N/A	-6	-37	-37	N/A
3/31/2021	N/A	-5	-34	-34	N/A
12/31/2020	N/A	-6	-35	-35	N/A
9/30/2020	N/A	-44	-35	-35	N/A
6/30/2020	N/A	-46	-38	-38	N/A
3/31/2020	N/A	-48	-38	-38	N/A
12/31/2019	N/A	-47	-37	-37	N/A
9/30/2019	N/A	-46	-37	-37	N/A
6/30/2019	N/A	-46	-38	-37	N/A
3/31/2019	N/A	-44	-39	-39	N/A
12/31/2018	N/A	-47	-41	-41	N/A
9/30/2018	N/A	-48	-44	-44	N/A
6/30/2018	N/A	-51	N/A	-44	N/A
3/31/2018	N/A	-54	N/A	-45	N/A
12/31/2017	N/A	-56	N/A	-46	N/A
9/30/2017	N/A	-55	N/A	-45	N/A
6/30/2017	N/A	-52	N/A	-41	N/A
3/31/2017	N/A	-46	N/A	-35	N/A
12/31/2016	N/A	-36	N/A	-28	N/A
9/30/2016	N/A	-31	N/A	-22	N/A
6/30/2016	N/A	-24	N/A	-19	N/A
3/31/2016	N/A	-36	N/A	-15	N/A
12/31/2015	N/A	-31	N/A	-11	N/A
9/30/2015	N/A	-25	N/A	-7	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CRVS de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CRVS de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CRVS de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CRVS ( 78.7% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van CRVS ( 78.7% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CRVS naar verwachting over 3 jaar hoog zal zijn

Corvus Pharmaceuticals Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 9.1% to US$7.50

Price target decreased to US$2.50

Price target increased to US$6.38

Price target increased to US$6.30

Price target increased to US$7.38

Price target decreased to US$6.50

Recent updates

Corvus Pharmaceuticals, Inc. Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Corvus Pharmaceuticals: The Market Likes The Story

Corvus Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy

Corvus Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Corvus Pharmaceuticals, Inc Grants FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Corvus Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Corvus Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $30.567011 million.

Corvus Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $30.567011 million.

Corvus Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Price target increased by 9.1% to US$7.50

Corvus Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 19, 2024

New minor risk - Market cap size

Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

New major risk - Revenue and earnings growth

Corvus Pharmaceuticals, Inc. Appoints Jeffrey Arcara as Chief Business Officer

Corvus Pharmaceuticals Announces Demise of Edith P. Mitchell, Member of the Board of Directors

Corvus Pharmaceuticals, Inc. Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial

New major risk - Financial position

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Corvus Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Corvus Pharmaceuticals, Inc. Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Corvus Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Corvus Pharmaceuticals, Inc. Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference

New minor risk - Market cap size

Corvus Pharmaceuticals, Inc. Presents New Cpi-818 Interim Data At the International Conference on Malignant Lymphoma

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

Corvus Pharmaceuticals, Inc. Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Price target decreased to US$2.50

Insufficient new directors

Corvus Pharmaceuticals, Inc. to Present Updated CPI-818 (ITK Inhibitor) Data At the American Society of Hematology Annual Meeting & Exposition

Corvus Pharmaceuticals Receives Written Notice from the Staff of the Listing Qualifications Department of Nasdaq

Corvus Pharmaceuticals, Inc. Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer

Corvus Pharmaceuticals, Inc. Announces Partner Angel Pharmaceuticals Receives IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China

Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China

We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Corvus Pharmaceuticals, Inc. Provides Business and Clinical Update

Corvus Pharmaceuticals, Inc. Appoints Dr. James Rosenbaum as Senior Vice President of Research

Price target increased to US$6.38

Insufficient new directors

Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

Chief Financial Officer recently bought US$77k worth of stock

Corvus Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Insufficient new directors

Corvus Pharmaceuticals, Inc. Announces New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as A Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation

We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Checking In On Corvus Pharmaceuticals

Price target increased to US$6.30

Corvus Pharmaceuticals Provides Updates on Mupadolimab

Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Corvus Pharmaceuticals, Inc. Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

Independent Director Steve Krognes has left the company

Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target

Price target increased to US$7.38

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

Co-Founder recently bought US$100k worth of stock

Price target decreased to US$6.50

Co-Founder recently bought US$350k worth of stock

The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

New 90-day high: US$4.28

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19